Scientists Try to Unravel the Riddle of Too Much

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone

Scientists Try to Unravel the Riddle of Too Much Sleep

Getting too little sleep is bad for your health. But getting too much—as wonderful as it may sound to some—can be problematic too.

Getting too little sleep is bad for your health, but getting too much can be problematic. WSJ's Melinda Beck and Emory University sleep researcher Dr. David Rye have details on Lunch Break. Photo: Courtesy of Anna Sumner.

The powerful need to nap during the day can be a warning sign of many health issues, from diabetes to depression, low thyroid or obstructive sleep apnea. When doctors rule out such explanations, it is called "primary hypersomnia," an umbrella term for several conditions that make sufferers crave sleep, despite getting 70 hours or more per week. One of the best known is narcolepsy, a neurological disorder that causes sudden, irresistible bouts of daytime dozing. Other forms aren't well understood.

Recently, researchers at Emory University in Atlanta have begun to unravel the mystery of this often-debilitating condition. They've found that some sufferers have a substance in their cerebrospinal fluid that acts like a natural sleeping pill. They think as many as 1 in 800 Americans may have the substance and that it may be a factor in other conditions that involve excessive drowsiness.

Many people with hypersomnia go undiagnosed, experts say. The excessive sleep urges often begin in late adolescence, and are easy to confuse with typical teenage sleep issues.

Raymond McCrea Jones for The Wall Street Journal

After Anna Sumner, an Atlanta attorney, suffered sleeping binges of more than 50 hours at a stretch, doctors discovered the culprit: a substance in her spinal fluid.

"It tends to hit people in their young, formative years when they are trying to get started in a profession or having a family," says Dr. David Rye, a professor of neurology at Emory and lead author of a paper on the discovery, published last month in the journal Science Translational Medicine. "A lot of them get dismissed as lazy, or as drug seekers."

Researchers now know that this condition "is something real," says Andrew Jenkins, an associate professor of neuroscience, molecular and system pharmacology at Emory. "We know why you're sleepy—your brain is sedating itself," he says.

The Emory team discovered the mysterious sleep agent, or "somnogen," when Anna Sumner, a young Atlanta attorney, sought help at the sleep clinic in 2005. After napping prodigiously through college and law school (she says roommates at Princeton made up stories to cover for her), her sleep cravings began intensifying in her 20s. At one point, she says, "I'd go to bed one night and wake up two days later."

When the spells' frequency increased from once every two months to once a week, she says, "I had to take a leave from work."

After standard treatment with stimulants stopped working, the Emory doctors discovered that a substance in Ms. Sumner's spinal fluid was supercharging GABA, a natural sleep-inducing brain chemical. The effect was like being under constant twilight sedation. "I don't know how she was able to function," says Dr. Jenkins, whose team decided to try treating her with a drug called flumazenil, used in emergency rooms to counteract overdoses of sedatives. After several days in the hospital on an IV drip, she suddenly opened her eyes and said, "I feel alive!"

She has been taking it in a specially made lozenge form since then, and is feeling happily alert—and just learned she will be made a partner next year.

The Emory researchers think this same sleep-inducing substance in spinal fluid may play a role in other conditions that involve excessive drowsiness. They still haven't identified the exact chemical. But they can test for it in other patients by watching how their spinal fluid acts on GABA in a laboratory setting.

So far, they have found the somnogen in the spinal fluid of 32 sleep-clinic patients. They tested flumazenil on seven of them and found that it restored alertness in all of them to differing degrees. "I think what we've discovered is the biology. And the question is, what syndromes is it relevant to?" says Dr. Rye.

One may be narcolepsy, those irresistible sleep attacks that can hit multiple times a day. Sufferers go into REM sleep immediately when they nap, and tend to wake up refreshed—at least temporarily. Some also have cataplexy, which involves sudden loss of muscle control.

A rarer form of hypersomnia, called Kleine-Levin syndrome, occurs almost exclusively in teenage boys. Sufferers sleep for several days at a time, and when they wake up, they are irritable, ravenously hungry and sometimes hypersexual.

Dr. Rye and his colleagues have found the sleep-inducing spinal fluid in patients previously diagnosed with both conditions. They are also working with the Centers for Disease Control and Prevention and hope to test for it in blood samples from people with chronic fatigue syndrome. They are also tracking how it travels in families. One-third of the 32 patients in the study have relatives with excessive sleepiness to varying degrees.

Since the study appeared, they have been fielding calls from other patients and sleep clinics—95 last week alone. "There is a huge unmet need of people who identify with Anna," says Dr. Rye, referring to Ms. Sumner.

Traditional treatments for hypersomnia, including stimulants such as Provigil, have proven to be effective sometimes with conditions like narcolepsy. But side effects can include a feeling of being "revved up."

Flumazenil, the drug used to treat Ms. Sumner, is proving hard to come by. Since it went off patent in 2008, the amount of the generic version produced annually for all of North America—enough to counteract 10,000 sedative overdoses—would supply only a handful of patients like Ms. Sumner, Emory researchers say.

But they are investigating other drugs that may have the same effect. Past research shows that one class of antibiotics may have a similar action at GABA receptors.

Of course, the vast majority of people with excessive daytime sleepiness don't have hypersomnia—most just don't get enough sleep at night. Shelby Harris, director of the Behavioral Sleep Medicine Program at Montefiore Medical Center in Bronx, N.Y., recommends that patients get at least eight hours of sleep nightly for two weeks before exploring other causes. "Make sleep a priority, and if that fixes it, great," she says. "If not, mention it to your primary-care doctor."

Indeed, many underlying health issues can also make people drowsy, including thyroid conditions, hormonal changes, vitamin deficiencies and infections; some can be ruled in or out with blood tests. Sleepiness is also a side effect of many medications, alcohol use or psychiatric conditions.

So many factors can affect alertness and energy levels, and they vary so much over the life span, that many people with sleep disorders never realize they have one. They often mask it with coffee or view drowsiness as just a fact of life.

Dr. Harris also recommends that people who think they are excessively sleepy keep track of when the drowsiness occurs. Nodding off after dinner or wanting to sleep till noon could indicate circadian rhythm disorders. "Afternoon slump"—the urge to nap at your desk after lunch—is a normal dip in the body's 24-hour clock.

"I tell patients to go out and take a walk when that happens," says Dr. Harris. "Being exposed to light can be more alerting than a cup of coffee."

Write to Melinda Beck at melinda.beck@wsj.com

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Louisiana's Musical Legacy Gets a Boost from Foundation

Updated Category News Views 201

Preserving the Tunes of the Bayou Well, if that ain't music to your ears! The Louisiana First Horizon Foundation is sliding into the spotlight with news that's bound to strike a chord with any lover of the state's iconic rhythms. They're diving in deep, backing the Louisiana Music Museum right in the heart of Lafayette. Now, that ain't just another charity stunt; it's a...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 151

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
Future FinTech Under Investigation: Shareholder Impact Looms

Updated Category News Views 81

Future FinTech Faces Legal Scrutiny When the walls close in under financial suspicion, the spotlight can burn brighter than any anticipated market gain. That's precisely what Future FinTech Group Inc. (NasdaqCM: FTFT) is up against now. Kahn Swick & Foti, LLC, featuring the ex-Attorney General of Louisiana, Charles C. Foti, Jr., has begun scrutinizing the actions of...

Continue Reading
AXON Revenue Forecast Cut Spurs Legal Investigation

Updated Category News Views 135

Axon's Revenue Forecast Takes a Hit Listen up, folks. Axon Enterprise, Inc. (NASDAQ: AXON) has stirred the pot, cutting their 2026 revenue forecast faster than you can say "counter-drone deployment." Back in August, they were riding high on their second-quarter call, raising their growth forecast to a cheerful 32%-34%. Fast forward to November, and it's been slashed to...

Continue Reading
Cultural Bridges and Mazu's Spirit: Gen Z's Role

Updated Category News Views 138

Youthful Energy Revives Ancient Traditions Over in Putian, China, you'd have seen a curious sight in late October—hundreds of young folks from over 20 corners of the globe gathering not for a concert or some influencer meet-up, but to dive into Mazu's legacy. This ain't your typical cultural event. More than 200 Gen Z representatives came together, bridging their...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 73

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading
CleanSpark Sets Investor Events with Promising Outlook

Updated Category News Views 184

CleanSpark's Strategy Gets the Spotlight Looks like CleanSpark's stepping up to the plate, folks. They're shouting from the rooftops about hitting the upcoming investor events, and it’s no small potatoes. The company’s lined up a string of high-profile conferences, showcasing their ambition to stay ahead in the energy and data center games. We're talking about the...

Continue Reading
Century Lithium's 2026 AGM Time Clarification Issued

Updated Category News Views 129

Time Zone Confusion No More Ah, time zones. They just keep finding ways to trip up the folks at Century Lithium. The company’s got itself in a twist over when the Annual General Meeting's supposed to kick off. Turns out, they've clarified the timing for their 2026 AGM—it’s stamped for 10:00 a.m. Pacific Time. British Columbia’s ditched the seasonal time change, so...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 77

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
AZZ Inc.'s 2026 Sustainability Report: A Closer Look

Updated Category News Views 231

Diving into AZZ's Sustainability Commitment AZZ Inc., known in the trading circles as NYSE:AZZ, has just dropped its 2026 Sustainability Report and it’s quite the document to chew on. This ain't your typical corporate fluff. Tom Ferguson, the man steering the AZZ ship, laid it down plain and simple. This report isn’t just about ticking boxes for ESG; it’s reflecting...

Continue Reading

Top 5 Most Recently Viewed Articles

ImmunityBio Advances Towards EU Approval for Cancer Treatment

Updated Category News Views 95

ImmunityBio's Journey Towards EU Approval The European Medicines Agency (EMA) has made a significant recommendation toward approving ImmunityBio, Inc.’s Anktiva (nogapendekin alfa inbakicept), intended for use alongside Bacillus Calmette-Guérin (BCG) for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Clinical Trial Results and Findings This...

Continue Reading
Temperature Monitoring Systems Set to Reach $5.66 Billion by 2030

Updated Category News Views 139

Temperature Monitoring Systems Market Analysis and Growth Projections The temperature monitoring systems market, valued at USD 3.80 billion recently, is on a promising trajectory. It is expected to expand at a compound annual growth rate (CAGR) of 5.3%, reaching an impressive USD 5.66 billion by 2030. This growth can be attributed to several factors, including...

Continue Reading
Comparative Insights on Apple and Its Competitors' Performance

Updated Category News Views 336

Performance Insights into Apple and Industry Competitors In the ever-evolving realm of technology, understanding the dynamics of company performance is vital for investors and analysts. This analysis focuses on Apple Inc. (NASDAQ: AAPL) and its key competitors in the Technology Hardware, Storage & Peripherals sector. We'll delve into essential financial metrics, market...

Continue Reading
X Financial Achieves Impressive Growth in Recent Earnings

Updated Category News Views 108

X Financial Reveals Strong Q2 Performance X Financial (NYSE: XYF), a prominent player in the fintech industry, has reported robust financial results that highlight its significant growth and commitment to enhancing its service offering. The company recently disclosed its unaudited financial results for the second quarter, and the figures are quite remarkable. Q2 2025...

Continue Reading
Tyra Biosciences to Engage Investors at Major Conferences

Updated Category News Views 290

Tyra Biosciences to Engage Investors at Major Conferences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a pioneering biotechnology company dedicated to crafting next-generation precision medicines with a keen focus on Fibroblast Growth Factor Receptor (FGFR) biology. The company has great momentum as it takes strides in engaging with investors at a series of crucial investor...

Continue Reading